Provided by Tiger Trade Technology Pte. Ltd.

Context Therapeutics Inc.

0.3004
-0.0186-5.83%
Post-market: 0.32000.0196+6.52%19:45 EDT
Volume:1.19M
Turnover:362.62K
Market Cap:27.60M
PE:-0.62
High:0.3310
Open:0.3310
Low:0.2965
Close:0.3190
52wk High:3.62
52wk Low:0.2965
Shares:91.88M
Float Shares:63.73M
Volume Ratio:1.04
T/O Rate:1.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4828
EPS(LYR):-0.3800
ROE:-76.14%
ROA:-45.70%
PB:0.72
PE(LYR):-0.79

Loading ...

Context Therapeutics Doses First Patient in Phase 1 Trial of CT-202 Bispecific Antibody

Reuters
·
Sep 09

Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of Ct-202

THOMSON REUTERS
·
Sep 09

Context downgraded to Market Perform from Outperform at LifeSci Capital

TIPRANKS
·
Aug 07

Ireland's GH Research Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 06

BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move

Benzinga Earnings
·
Aug 06

Context Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Context Therapeutics Q2 FY26 Net Loss Widens 65% to $14.56 Million Year over Year

Reuters
·
Aug 06

Context Therapeutics Inc. Q2 Net Income USD -14.6 Million

THOMSON REUTERS
·
Aug 06

Context Therapeutics Inc. Q2 Basic EPS USD -0.15

THOMSON REUTERS
·
Aug 06

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

THOMSON REUTERS
·
Aug 06

Context Therapeutics Receives Nasdaq Minimum Bid Price Notice

TIPRANKS
·
Aug 01

Context Therapeutics Gets NASDAQ Notice for Failing $1 Minimum Bid Price Rule

Reuters
·
Aug 01

Context Therapeutics Inc Expected to Post a Loss of 9 Cents a Share - Earnings Preview

Reuters
·
Aug 01

Context Therapeutics Grants New Hire Stock Options for 146,000 Shares at $0.7 Each

Reuters
·
Jul 11

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 11

Context Therapeutics Advances First-in-Human CT-202 Trial, Setting Up a New Nectin-4 Oncology Catalyst

TIPRANKS
·
Jul 10

Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes

THOMSON REUTERS
·
Jul 07

Context Therapeutics Shareholders Approve Increase in Authorized Common Shares to 300 Million

Reuters
·
Jun 27

Context Therapeutics selloff brings buying opportunity, says JonesResearch

TIPRANKS
·
Jun 16

Analysts Offer Insights on Healthcare Companies: Dyadic International (DYAI) and Context Therapeutics (CNTX)

TIPRANKS
·
Jun 16